within Pharmacolibrary.Drugs.ATC.V;

model V08CA09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00011999999999999999,
    k12             = 0.081,
    k21             = 0.081
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadobutrol is a nonionic, macrocyclic gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance the visualization of blood vessels and detect abnormalities in the brain, spine, and other tissues. It is widely approved and used in clinical practice for diagnostic imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single intravenous administration.</p><h4>References</h4><ol><li><p>Staks, T, et al., &amp; Platzek, J (1994). Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. <i>Investigative radiology</i> 29(7) 709–715. DOI:<a href=\"https://doi.org/10.1097/00004424-199407000-00008\">10.1097/00004424-199407000-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7960618/\">https://pubmed.ncbi.nlm.nih.gov/7960618</a></p></li><li><p>Scott, LJ (2018). Gadobutrol: A Review in Contrast-Enhanced MRI and MRA. <i>Clinical drug investigation</i> 38(8) 773–784. DOI:<a href=\"https://doi.org/10.1007/s40261-018-0674-9\">10.1007/s40261-018-0674-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30006819/\">https://pubmed.ncbi.nlm.nih.gov/30006819</a></p></li><li><p>Hahn, G, et al., &amp; Mentzel, HJ (2009). Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. <i>Investigative radiology</i> 44(12) 776–783. DOI:<a href=\"https://doi.org/10.1097/RLI.0b013e3181bfe2d2\">10.1097/RLI.0b013e3181bfe2d2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19858730/\">https://pubmed.ncbi.nlm.nih.gov/19858730</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA09;
